Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Prevention retrospective analysis of the post-transfusion reactions and complications

Prevention retrospective analysis of the post-transfusion reactions and complications
Полный текст  

Abstract

Introduction. Prevention of posttransfusion complications (PTR) is an urgent task of transfusion medicine. To date, modern technologies have been introduced in the Republic of Uzbekistan to prevent the development of febrile non-hemolytic reactions, graft-versus-host disease and reduce the risk of transmission of infectious and bacterial infections to patients receiving blood transfusion. The aim of the study. Conducting an analysis of the causes of post-transfusion complications over a 5-year period, as well as developing recommendations for the introduction of modern technologies into blood processing processes and reducing the risk of post-transfusion complications. Materials and methods. We have analyzed 12 cases of serious posttransfusion complications that have developed in medical institutions of the republic over the past 5 years. The production processes of the Blood Service of the Republic of Kazakhstan on the introduction of new methods of screening and processing of donated blood, including a two-stage method of testing for markers of hemotransmissive infections, leukofiltration, irradiation (irradiation) of blood components, were analyzed. Results. According to the materials of the Republican Commission for the Analysis and Prevention of post-transfusion complications of the Ministry of Health of the Republic of Uzbekistan, we have identified 12 cases of serious post-transfusion complications, of which 6 were fatal in medical institutions of the republic. Conclusions. The introduction of modern technologies into the practice of the blood service, strict compliance with the rules of blood transfusion and increasing the knowledge of practitioners on blood transfusion can significantly reduce the risk of post-transfusion complications and ensure the quality and safety of transfusion therapy in medical institutions of the republic.

About the authors

Махмудова Майя Рафиковна, кандидат медицинских наук, врач методист организационно-методического отдела Республиканского Центра Переливания крови МЗ, Ташкент Республика Узбекистан

Makhmudova Maya Rafikovna, candidate of medical sciences, physician methodologist of the organizational and methodological department of the Republican Center for Blood Transfusion of the Ministry of Health, Tashkent, Republic of Uzbekistan

Махмудова Майя Рафиковна, медицина илимдеринин кандидаты, Саламаттык сактоо министрлигинин Республикалык кан куюу борборунун уюштуруу-методикалык бөлүмүнүн врач-методисти, Өзбекстан Республикасы, Ташкент шаары.

References

1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12

1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12

1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12

Для цитирования

Махмудова М.Р. Профилактика и ретроспективный анализ пострансфузионных реакций и осложнений. Научно-практический журнал «Здравоохранение Кыргызстана» 2024, № 3, с. 95-99.https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99

For citation

Makhmudova M.R. Prevention retrospective analysis of the post-transfusion reactions and complications. Scientific and
practical journal “Health care of Kyrgyzstan” 2024, No.3, p. 95-99.  https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99

Цитата үчүн

Махмудова М.Р. Трансфузиядан кийинки реакциялардын жана татаалдашуулардын алдын алуу жана ретроспективдүү талдоо. Кыргызстандын саламаттык сактоо илимий-практикалык журналы 2024, № 3, б. 95-99. https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99

Authors Makhmudova M.R.
Link doi.org https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99
Pages 95-99
Keywords Leukofiltration, Posttransfusion complications (PTR), Irradiation, Viral activation
Russian
Об авторах

Махмудова Майя Рафиковна, кандидат медицинских наук, врач методист организационно-методического отдела Республиканского Центра Переливания крови МЗ, Ташкент Республика Узбекистан

Полный текст

PDF (RUS)

Список литературы

1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12

Для цитирования

Махмудова М.Р. Профилактика и ретроспективный анализ пострансфузионных реакций и осложнений. Научно-практический журнал «Здравоохранение Кыргызстана» 2024, № 3, с. 95-99.https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99

English
About authors

Makhmudova Maya Rafikovna, candidate of medical sciences, physician methodologist of the organizational and methodological department of the Republican Center for Blood Transfusion of the Ministry of Health, Tashkent, Republic of Uzbekistan

References

1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12

For citation

Makhmudova M.R. Prevention retrospective analysis of the post-transfusion reactions and complications. Scientific and
practical journal “Health care of Kyrgyzstan” 2024, No.3, p. 95-99.  https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99

Kyrgyz
Авторлор жөнүндө

Махмудова Майя Рафиковна, медицина илимдеринин кандидаты, Саламаттык сактоо министрлигинин Республикалык кан куюу борборунун уюштуруу-методикалык бөлүмүнүн врач-методисти, Өзбекстан Республикасы, Ташкент шаары.

Шилтемелер

1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12

Цитата үчүн

Махмудова М.Р. Трансфузиядан кийинки реакциялардын жана татаалдашуулардын алдын алуу жана ретроспективдүү талдоо. Кыргызстандын саламаттык сактоо илимий-практикалык журналы 2024, № 3, б. 95-99. https://dx.doi.org/10.51350/zdravkg2024.3.9.13.95.99

Views: 235
Copyright MAXXmarketing GmbH
JoomShopping Download & Support